Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Last updated: February 22, 2017
Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Overall Status: Completed

Phase

3

Condition

Hiv/aids

Hiv Infections

Aids And Aids Related Infections

Treatment

N/A

Clinical Study ID

NCT01114425
382426005_1
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The objective are to assess the nature and incidence of drug intolerance observed with a new antiretroviral triple therapy, Truvada® [0-0-1] + Isentress® 400 mg tablets [1-0-1], prescribed in a setting of the treatment of individuals with recent exposure to a risk of transmission of HIV infection and to compare the results with those of previous studies conducted according to the same methodology, with other combinations of antiretrovirals.

Eligibility Criteria

Inclusion

Inclusion criteria

  • age 18 years or over

  • consultation immediately following exposure to the risk of transmission of HIV infection (less than 48 hours, except in the case of rape when this period may be increased to a maximum of 120 hours)

  • person capable of understanding the principle of the study and giving his/her informed consent

Exclusion criteria

  • subjects recently exposed to a risk of transmission of HIV infection in which the source patient is known to be infected with HIV and treated, and whose therapeutic history justifies the introduction of PET other than that proposed in this study

  • subjects with a contraindication to the prescription of Truvada® and/or Isentress® (renal impairment, allergy, etc.)

  • subjects previously treated with phenytoin, phenobarbital and rifampicin, since combination with raltegravir is contraindicated subjects known to be infected with hepatitis B virus, whether or not treated with lamivudine

  • subjects refusing to take part in the study

  • pregnant women

Study Design

Total Participants: 149
Study Start date:
November 01, 2010
Estimated Completion Date:
December 01, 2012

Connect with a study center

  • GERES

    Paris,
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.